Calgent has completed Phase I clinical trials for CAL056 cancer drug in both Taiwan and the U.S., confirming its safety in patients with resistant or refractory solid tumors, with no serious adverse events (SAE) observed. This marks a significant step forward in Calgent’s clinical trial progress.
